2160
GNI Group Co., Ltd.
2026/02/12
The acquisition of Gyre Pharmaceuticals shares is planned to be completed by the end of December 2026, with full-year earnings guidance revisions handled cautiously in light of year-end external environmental changes. The conditional approval application for F351 in China is scheduled for the first half of 2026.
